FY2025 Earnings Estimate for Insmed Incorporated (NASDAQ:INSM) Issued By HC Wainwright

Insmed Incorporated (NASDAQ:INSM) – Investment analysts at HC Wainwright upped their FY2025 earnings per share estimates for shares of Insmed in a report released on Monday, July 8th. HC Wainwright analyst A. Fein now forecasts that the biopharmaceutical company will post earnings of ($3.36) per share for the year, up from their previous estimate of ($3.54). HC Wainwright currently has a “Buy” rating and a $90.00 price target on the stock. The consensus estimate for Insmed’s current full-year earnings is ($4.71) per share. HC Wainwright also issued estimates for Insmed’s FY2026 earnings at ($1.92) EPS, FY2027 earnings at $0.14 EPS and FY2028 earnings at $2.14 EPS.

Insmed (NASDAQ:INSM) last announced its earnings results on Thursday, May 9th. The biopharmaceutical company reported ($1.06) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.22) by $0.16. The company had revenue of $75.50 million for the quarter, compared to the consensus estimate of $77.76 million. The company’s revenue was up 15.8% compared to the same quarter last year. During the same period last year, the firm posted ($1.17) EPS.

Several other research analysts have also recently commented on INSM. Evercore ISI raised their target price on Insmed from $42.00 to $75.00 and gave the stock an “outperform” rating in a research report on Friday, June 21st. Guggenheim lifted their price objective on Insmed from $70.00 to $95.00 and gave the company a “buy” rating in a report on Tuesday. Mizuho boosted their price target on Insmed from $36.00 to $82.00 and gave the company a “buy” rating in a research note on Friday, June 7th. TD Cowen boosted their target price on shares of Insmed from $45.00 to $67.00 and gave the company a “buy” rating in a research note on Wednesday, May 29th. Finally, Morgan Stanley lifted their price target on shares of Insmed from $40.00 to $43.00 and gave the company an “overweight” rating in a report on Friday, May 10th. One research analyst has rated the stock with a hold rating and sixteen have assigned a buy rating to the stock. According to MarketBeat, Insmed has an average rating of “Moderate Buy” and an average target price of $71.88.

Insmed Stock Up 5.4 %

Insmed stock opened at $77.03 on Wednesday. The stock has a market cap of $11.45 billion, a price-to-earnings ratio of -14.73 and a beta of 1.16. Insmed has a 12 month low of $20.01 and a 12 month high of $77.26. The business has a 50 day moving average price of $50.32 and a two-hundred day moving average price of $35.59.

Institutional Trading of Insmed

Institutional investors and hedge funds have recently modified their holdings of the stock. Rafferty Asset Management LLC raised its holdings in Insmed by 17.4% in the fourth quarter. Rafferty Asset Management LLC now owns 321,087 shares of the biopharmaceutical company’s stock worth $9,950,000 after purchasing an additional 47,563 shares during the period. Kingdon Capital Management L.L.C. acquired a new stake in shares of Insmed during the fourth quarter worth $12,551,000. Artia Global Partners LP acquired a new position in Insmed in the 4th quarter worth $2,322,000. Norges Bank bought a new position in Insmed during the 4th quarter worth about $45,029,000. Finally, Walleye Capital LLC bought a new stake in shares of Insmed in the third quarter valued at about $1,820,000.

Insider Activity

In related news, CFO Sara Bonstein sold 220,564 shares of Insmed stock in a transaction dated Wednesday, May 29th. The stock was sold at an average price of $50.00, for a total value of $11,028,200.00. Following the completion of the sale, the chief financial officer now directly owns 117,481 shares in the company, valued at $5,874,050. The sale was disclosed in a filing with the SEC, which is available through the SEC website. In related news, insider John Drayton Wise sold 5,088 shares of Insmed stock in a transaction on Tuesday, May 14th. The stock was sold at an average price of $25.47, for a total transaction of $129,591.36. Following the completion of the sale, the insider now directly owns 123,259 shares of the company’s stock, valued at $3,139,406.73. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, CFO Sara Bonstein sold 220,564 shares of the stock in a transaction dated Wednesday, May 29th. The shares were sold at an average price of $50.00, for a total value of $11,028,200.00. Following the completion of the transaction, the chief financial officer now directly owns 117,481 shares in the company, valued at approximately $5,874,050. The disclosure for this sale can be found here. In the last ninety days, insiders sold 295,842 shares of company stock valued at $13,762,062. Company insiders own 4.60% of the company’s stock.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.